Kalos Therapeutics

Kalos Therapeutics is a biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer.

Contents

• Kalos therapeutics inc
• Azbio expo 2014 kalos therapeutics
• Board Members
• Affiliated Organizations
• References

Kalos has been covered by ABC News on Good Morning America, and profiled in Business Week and Time Magazine. The company aggressively targets diseases caused by an abnormally high growth rate of cells (hyper proliferation), and is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.

KT-220, the current lead drug candidate, demonstrates remarkably broad anti-cancer activity. KT-220 has inhibited the growth of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.